Research programme: anticancer antibodies - Affitech/RocheAlternative Names: AT 006; LC 06; LC 08
Latest Information Update: 10 Aug 2012
At a glance
- Originator Affitech AS
- Developer Affitech A/S; Roche
- Class Bispecific antibodies; Monoclonal antibodies
- Mechanism of Action Angiopoietin-1 inhibitors; Angiopoietin-2 inhibitors; Vascular endothelial growth factor A inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer